Key result
Eplerenone improves LV function and reduces IL-1β and sST2 in a post-MI rat model.
Why the study?
Does eplerenone improve LV function and modulate IL-1β and IL-33/sST2 signaling in rats with LV systolic dysfunction after acute MI?
Population
Rats with an experimental model of left ventricular systolic dysfunction after acute myocardial infarction
Comparison
Eplerenone or anakinra vs No treatment (MI group) and sham animals
Design
Preclinical, randomly assigned
Authors
Loading...
Eplerenone may improve post-MI LV function via IL-1β/sST2; extends animal evidence but leaves open human applicability.
RCT (n=30)
Randomly assigned
Does eplerenone improve LV function and modulate IL-1β and IL-33/sST2 signaling in rats with LV systolic dysfunction after acute MI?
Eplerenone improves LV function and reduces fibrosis and inflammatory markers by downregulating IL-1β and sST2 expression in a rat model of post-MI LV dysfunction.
Chen et al. (2018) conducted an RCT in Left ventricular systolic dysfunction after acute myocardial infarction (n=30). Eplerenone or anakinra vs. No treatment (MI group) and sham was evaluated on Left ventricular function, IL-1β, IL-33/sST2, and cardiac fibrosis biomarkers. Eplerenone improved left ventricular function and reduced expression of IL-1β and sST2 in an experimental rat model of systolic dysfunction after acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: